Visalytics
Visalytics
approved EB-2 (NIW)

Ph.D. Candidate

Pharmaceutical Technology · Syria · 2025-05-13

Processing Time
343 days
Decision Date
2025-05-13
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop next-generation controlled-release drug delivery systems (CRDDSs) that release medications at controlled rates to improve efficacy and patient compliance for chronic diseases like diabetes and hypertension. His work involves integrating botanical materials into drug matrices to create low-cost, biocompatible alternatives to synthetic excipients. He plans to collaborate with U.S. pharmaceutical institutions to explore liposomal systems and stimuli-responsive materials for enhanced drug release.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The work addresses chronic conditions affecting 130 million Americans and offers cost-effective pharmaceutical solutions.

2 Well-positioned to Advance the Endeavor Met

The petitioner has a Ph.D. candidacy background, 28 peer-reviewed publications, and over 300 citations validating his expertise.

3 Balance of Interests Met

The petitioner's unique contributions to sustainable pharmaceutical design and drug delivery efficiency make his presence beneficial to the U.S. regardless of labor certification.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 28 peer-reviewed journal articles and 2 conference papers which garnered over 300 citations. Evidence showed his papers ranked in the top 10–20% of the Pharmacology & Toxicology field, and he demonstrated professional standing through peer review for the Journal of Experimental Pharmacology. The case satisfied all three Dhanasar prongs by linking his innovations to the management of chronic diseases affecting 130 million Americans.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Conference Presentations
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Scientist

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
New Jersey 51 days 2025-03-17
The petitioner proposes to develop novel and advanced drug delivery systems for new drug products to support animal studies and clinical trials across a wide scope of treatment indications. His work specifically focuses on improving the bioavailability, precision, and controlled release of medications to address the global burden of cardiovascular diseases (CVDs).
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
Massachusetts 13 days 2021-12-20
The petitioner proposes to develop safe and effective drug delivery platforms, including lipid-based nanoparticles, extracellular vesicles, oral biotherapeutics, and hydrogels. This work utilizes techniques such as microfluidics and high-performance liquid chromatography to facilitate improved targeting and dosage for treating rheumatoid arthritis, diabetes, and cancer.
View Case

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) rfe approved
North Carolina 111 days 2025-02-08
The petitioner proposes to improve existing therapies by applying advanced pharmaceutical principles to commercialize biopharmaceuticals and pharmaceuticals. The work focuses on developing innovative drug solubility enhancement methods and non-invasive oral drug delivery systems to treat serious diseases like cancer, AIDS, and kidney failure.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Syria

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-05-13.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 343 days
Criteria Met 3 / 3
Evidence Types 7

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Syria All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist